公开(公告)号：US20100168110A1

公开(公告)日：2010-07-01

申请号：US12224168

申请日：2008-06-02

申请人： Laxmikant Chhipa ,  Shitalkumar Zambad ,  Ramesh Gupta ,  Davinder Tuli ,  Ashok Kasundra ,  Siralee Munshi ,  M. Amir Siddiqui ,  Subrat Kumar Bhattamisra ,  C. Dutt ,  Vijay Chauthaiwale

发明人： Laxmikant Chhipa ,  Shitalkumar Zambad ,  Ramesh Gupta ,  Davinder Tuli ,  Ashok Kasundra ,  Siralee Munshi ,  M. Amir Siddiqui ,  Subrat Kumar Bhattamisra ,  C. Dutt ,  Vijay Chauthaiwale

IPC分类号： A61K31/5377 ,  C07D231/20 ,  A61K31/415 ,  C07D403/06 ,  A61K31/4155 ,  C07D403/04 ,  C07D413/04 ,  A61K31/4245 ,  A61K31/506 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P3/00 ,  A61P5/14 ,  A61P17/00 ,  A61P9/00 ,  A61P25/24

CPC分类号： C07D403/06 ,  C07D231/12 ,  C07D231/14 ,  C07D231/18 ,  C07D403/10 ,  C07D403/12 ,  C07D409/04 ,  C07D413/06

摘要： The present invention discloses a novel thyroid like compounds of formula (I), wherein R1 R2, R3, R4 and Z are as defined in the specification, method for its preparation, composition containing such compounds and use of such compounds and composition as medicament. Further, compounds of formula (I) has significantly low binding affinity to thyroid receptors and thus considerably devoid of thyrotoxic effects. The invention also relates to the use of the compound of formula (I) for the preparation of a medicament for treating various disease conditions such as obesity, dyslipidemia, metabolic syndrome and co-morbidities associated with metabolic syndrome.

摘要翻译： 本发明公开了一种新颖的甲状腺样化合物，其中R1 R2，R3，R4和Z如本说明书中所定义，其制备方法，含有这些化合物的组合物以及这些化合物的用途和组合物作为药物。 此外，式（I）化合物对甲状腺受体具有显着低的结合亲和力，因此显着缺乏甲状腺毒性作用。 本发明还涉及式（I）化合物在制备用于治疗各种疾病状况如肥胖，血脂异常，代谢综合征和与代谢综合征相关的并发症的药物中的用途。